• Setanaxib (GKT831) achieved statistical significance (p=0.02) for primary endpoint with the 400mg BID versus placebo, after correction of nonnormal distribution (outliers) in 400mg OD
  • In advanced patients, setanaxib 400mg BID achieved significant reductions in GGT (-32%) and ALP (-24%)
  • Cash and cash equivalents of €4.5 million as of June 30, 2019, providing cash runway to April 2020Genkyotex (Euronext Paris & Brussels: FR0013399474 – GKTX), a biopharmaceutical company and the leader in NOX therapies, announced today positive post-hoc analysis of PBC phase 2 trial.

For More information,